People in the News
Life sciences investment group Abingworth Management, which holds a stake in Alnylam Pharmaceuticals, said this week that it has appointed Tim Haines as a partner.
Haines will be responsible for identifying and creating new businesses, as well as providing support for existing companies within the Abingworth portfolio, the firm said.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
You may already have institutional access!
Check if I qualify.
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.